Floatz logo

Lapine T-Lymphocyte Immune Globulin

Sickle Beta Thalassemia

M.D. Anderson Cancer CenterEarly Phase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Sickle Beta Thalassemia cohort.

Asset / SponsorPhaseRating
Hydroxyurea
Nova Laboratories Limited
Phase 1/2CCC
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 1/2CCC
Peripheral Blood Stem Cell Graft That Are Cd34+ Selected
Catherine Bollard
Phase 1CC
Fludarabine
M.D. Anderson Cancer Center
Early Phase 1C
Busulphan
M.D. Anderson Cancer Center
Early Phase 1C

View all 10 →

Same molecule, other indications

Lapine T-Lymphocyte Immune Globulin is also rated in:

bone marrow failure syndromeDormant
CCC
Indicative ·
48 / 100
View asset →
congenital amegakaryocytic thrombocytopeniaDormant
CCC
Indicative ·
48 / 100
View asset →
Diamond-Blackfan anemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →